Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

NCT03503409 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT03503409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03503409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 14, 2019
Completion date
April 2, 2027
Enrollment
68 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplastic syndromes